CN110290788A - 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途 - Google Patents

氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途 Download PDF

Info

Publication number
CN110290788A
CN110290788A CN201780077574.0A CN201780077574A CN110290788A CN 110290788 A CN110290788 A CN 110290788A CN 201780077574 A CN201780077574 A CN 201780077574A CN 110290788 A CN110290788 A CN 110290788A
Authority
CN
China
Prior art keywords
formula
bipolar disorder
disorder
bipolar
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780077574.0A
Other languages
English (en)
Chinese (zh)
Inventor
申惟轸
韩洗明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CN110290788A publication Critical patent/CN110290788A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780077574.0A 2016-12-14 2017-12-14 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途 Pending CN110290788A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
KR10-2016-0170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
CN110290788A true CN110290788A (zh) 2019-09-27

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780077574.0A Pending CN110290788A (zh) 2016-12-14 2017-12-14 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途

Country Status (14)

Country Link
US (1) US11571410B2 (https=)
EP (1) EP3556366B1 (https=)
JP (1) JP7208139B2 (https=)
KR (1) KR102635938B1 (https=)
CN (1) CN110290788A (https=)
AU (1) AU2017374458B2 (https=)
BR (1) BR112019011930A2 (https=)
CL (1) CL2019001618A1 (https=)
ES (1) ES3054693T3 (https=)
IL (1) IL267195B2 (https=)
MX (1) MX2019006940A (https=)
MY (1) MY199104A (https=)
WO (1) WO2018111008A1 (https=)
ZA (1) ZA201903747B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220117941A1 (en) * 2018-09-21 2022-04-21 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
WO2020060252A1 (ko) * 2018-09-21 2020-03-26 에스케이바이오팜 주식회사 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
JP7724776B2 (ja) * 2019-11-22 2025-08-18 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用医薬組成物及びその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067921A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
CN1503666A (zh) * 2001-02-27 2004-06-09 ����-������ҩƷ��˾ 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
CN101228138A (zh) * 2005-04-22 2008-07-23 Sk株式会社 神经治疗吡咯化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297732C (en) * 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
PL365588A1 (en) 2000-07-21 2005-01-10 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
CN101106972A (zh) 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
MX2009004798A (es) 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
PL2445890T3 (pl) 2009-06-22 2016-02-29 Sk Biopharmaceuticals Co Ltd Sposób wytwarzania estru (R)-1-arylo-2-tetrazoliloetylowego kwasu karbaminowego
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067921A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
CN1503666A (zh) * 2001-02-27 2004-06-09 ����-������ҩƷ��˾ 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
CN101228138A (zh) * 2005-04-22 2008-07-23 Sk株式会社 神经治疗吡咯化合物

Also Published As

Publication number Publication date
MY199104A (en) 2023-10-13
CA3046297A1 (en) 2018-06-21
EP3556366A1 (en) 2019-10-23
US20190314337A1 (en) 2019-10-17
US11571410B2 (en) 2023-02-07
AU2017374458A1 (en) 2019-07-04
CL2019001618A1 (es) 2019-08-23
EP3556366B1 (en) 2025-10-22
RU2019121913A (ru) 2021-01-15
WO2018111008A1 (ko) 2018-06-21
IL267195B1 (en) 2024-01-01
ES3054693T3 (en) 2026-02-05
IL267195A (https=) 2019-07-31
RU2019121913A3 (https=) 2021-04-21
KR102635938B1 (ko) 2024-02-13
AU2017374458B2 (en) 2023-03-02
MX2019006940A (es) 2019-09-06
JP7208139B2 (ja) 2023-01-18
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
JP2020502106A (ja) 2020-01-23
KR20190087572A (ko) 2019-07-24
BR112019011930A2 (pt) 2019-10-29
ZA201903747B (en) 2021-01-27

Similar Documents

Publication Publication Date Title
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
CN109475529B (zh) 氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
CN111432814B (zh) 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
JP2019516722A (ja) 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CN110267657A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
KR20210062029A (ko) 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
RU2796295C2 (ru) Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства
HK40015061A (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015213

Country of ref document: HK